•• Troussard X, Maître E, Cornet E. Hairy cell leukemia 2022: Update on diagnosis, risk-stratification, and treatment. Am J Hematol. 2022;97:226–36. This article is a comprehensive review that touches on future directions such as risk stratification and experimental treatments.
Article CAS PubMed Google Scholar
Grever MR, Abdel-Wahab O, Andritsos LA, et al. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood. 2017;129:553–60.
Article CAS PubMed PubMed Central Google Scholar
Epperla N, Zhao Q, Anghelina M, et al. Impact of sex on outcomes in patients with hairy cell leukemia (HCL): an HCL Patient Data Registry (PDR) analysis. J Clin Oncol. 2022. https://doi.org/10.1200/JCO.2022.40.16_suppl.7577.
De Propris MS, Musiu P, Intoppa S, et al. Hairy cell leukaemia with low CD103 expression: a rare but important diagnostic pitfall. Br J Haematol. 2022;198:e28–31.
Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36:1720–48.
Article PubMed PubMed Central Google Scholar
Kumar P, Gao Q, Chan A, Lewis N, Sigler A, Pichardo J, Xiao W, Roshal M, Dogan A. Hairy cell leukemia expresses programmed death-1. Blood Cancer J. 2020;10:1–4.
Robak P, Jesionek-Kupnicka D, Kupnicki P, Polliack A, Robak T. Bone lesions in hairy cell leukemia: diagnosis and treatment. Eur J Haematol. 2020;105:682–91.
Doma A, Škerget M, Žagar I. 18F-FDG PET/CT for staging and evaluation of therapy in a patient with unusual hairy cell leukemia presentation. Clin Nucl Med. 2019;44:e458–60.
Itchaki G, Gurevich K, Gorenberg M, Tadmor T. PB1885: the role of pet CT in hairy cell leukemia. HemaSphere. 2022;6:1764–5.
Article PubMed Central Google Scholar
Notarfranchi L, Russo F, Re F, Mancini C, Martella E, Falini B, Aversa F, Tiacci E. Hairy cell leukaemia mimicking multiple myeloma. Lancet Oncol. 2019;20:e187.
Rosen DS, Smith S, Gurbuxani S, Yamini B. Extranodal hairy cell leukemia presenting in the lumbar spine. J Neurosurg Spine. 2008;9:374–6.
Hammond WA, Swaika A, Menke D, Tun HW. Hairy cell lymphoma: a potentially under-recognized entity. Rare Tumors. 2017;9:6518.
Article PubMed PubMed Central Google Scholar
Matutes E, Morilla R, Owusu-Ankomah K, Houliham A, Meeus P, Catovsky D. The immunophenotype of hairy cell leukemia (HCL). Proposal for a scoring system to distinguish HCL from B-cell disorders with hairy or villous lymphocytes. Leuk Lymphoma. 1994;14 Suppl 1:57–61.
Jain D, Dorwal P, Gajendra S, Pande A, Mehra S, Sachdev R. CD5 positive hairy cell leukemia: a rare case report with brief review of literature. Cytometry B Clin Cytom. 2016;90:467–72.
Wang L, Tadros AS, Hoh CK, Wang H-Y. CD10-positive hairy cell leukemia involving multiple deep lymph nodes. Clin Lymphoma Myeloma Leuk. 2016;16:e51–3.
Kohla S, Ibrahim FA, Aldapt MB, ELSabah H, Mohamed S, Youssef R. A rare case of hairy cell leukemia with unusual loss of CD123 associated with COVID-19 at the time of presentation. Case Rep Oncol. 2020;13:1430–40.
Article CAS PubMed PubMed Central Google Scholar
Poret N, Fu Q, Guihard S, Cheok M, Miller K, Zeng G, Quesnel B, Troussard X, Galiègue-Zouitina S, Shelley CS. CD38 in hairy cell leukemia is a marker of poor prognosis and a new target for therapy. Cancer Res. 2015;75:3902–11.
Article CAS PubMed Google Scholar
Anghelina M, Epperla N, Rogers KA, et al. Down-regulation of CD25 antigen in hairy cell leukemia patients after treatment. Blood. 2018;132:4143.
Tiacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med. 2011;364:2305–15.
Article CAS PubMed PubMed Central Google Scholar
Tschernitz S, Flossbach L, Bonengel M, Roth S, Rosenwald A, Geissinger E. Alternative BRAF mutations in BRAF V600E-negative hairy cell leukaemias. Br J Haematol. 2014;165:529–33.
Article CAS PubMed Google Scholar
• Maitre E, Tomowiak C, Lebecque B, et al. Deciphering genetic alterations of hairy cell leukemia and hairy cell leukemia-like disorders in 98 patients. Cancers. 2022;14:1904. This article describes how mutations in MAP2K1 were the only genetic alteration associated with a poor prognosis.
Article CAS PubMed PubMed Central Google Scholar
Maitre E, Bertrand P, Maingonnat C, et al. New generation sequencing of targeted genes in the classical and the variant form of hairy cell leukemia highlights mutations in epigenetic regulation genes. Oncotarget. 2018;9:28866–76.
Article PubMed PubMed Central Google Scholar
Paillassa J, Maitre E, Troussard X. Hairy cell leukemia (HCL) and HCL variant: updates and spotlights on therapeutic advances. Curr Oncol Rep. 2022;24:1133–43.
Article CAS PubMed Google Scholar
Maral S, Albayrak M, Dagdas S, et al. Prognostic value of baseline serum lactate dehydrogenase level in patients with hairy cell leukemia. Clin Lymphoma Myeloma Leuk. 2020;20:e616–21.
Forconi F. Hairy cell leukaemia: biological and clinical overview from immunogenetic insights. Hematol Oncol. 2011;29:55–66.
Article CAS PubMed Google Scholar
Grever M, Kopecky K, Foucar MK, Head D, Bennett JM, Hutchison RE, Corbett WE, Cassileth PA, Habermann T, Golomb H. Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study. J Clin Oncol Off J Am Soc Clin Oncol. 1995;13:974–82.
•• Chihara D, Arons E, Stetler-Stevenson M, et al. Randomized phase II study of first-line cladribine with concurrent or delayed rituximab in patients with hairy cell leukemia. J Clin Oncol Off J Am Soc Clin Oncol. 2020;38:1527–38. Follow-up of a trial demonstrating the deeper and longer responses with the addition of rituximab which effectively is changing how first-line treatment is delivered.
Ravandi F. MRD in HCL: does it matter? Blood. 2018;131:2277–8.
Article CAS PubMed Google Scholar
Bohn J-P, Dietrich S. Treatment of classic hairy cell leukemia: targeting minimal residual disease beyond cladribine. Cancers. 2022;14:956.
Article CAS PubMed PubMed Central Google Scholar
• Ravandi F, Kreitman RJ, Tiacci E, et al. Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia. Blood Cancer J. 2022;12:165. This is the first consensus on the growing topic of MRD significance in HCL and its value on clinical practice.
Article PubMed PubMed Central Google Scholar
Chihara D, Kantarjian H, O’Brien S, et al. Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial. Br J Haematol. 2016;174:760–6.
Article CAS PubMed PubMed Central Google Scholar
Zinzani PL, Lauria F, Salvucci M, Rondelli D, Raspadori D, Bendandi M, Magagnoli M, Tura S. Hairy-cell leukemia and alpha-interferon treatment: long-term responders. Haematologica. 1997;82:152–5.
Moore JE, Delibert K, Baran AM, Evans AG, Liesveld JL, Zent CS. Targeted therapy for treatment of patients with classical hairy cell leukemia. Leuk Res. 2021;102:106522.
Article CAS PubMed Google Scholar
Daver N, Nazha A, Kantarjian HM, Haltom R, Ravandi F. Treatment of hairy cell leukemia during pregnancy: are purine analogues and rituximab viable therapeutic options. Clin Lymphoma Myeloma Leuk. 2013;13:86–9.
Article CAS PubMed Google Scholar
Perrotta K, Kiernan E, Bandoli G, Manaster R, Chambers C. Pregnancy outcomes following maternal treatment with rituximab prior to or during pregnancy: a case series. Rheumatol Adv Pract. 2021;5:rkaa074.
Article PubMed PubMed Central Google Scholar
Tiacci E, Park JH, De Carolis L, et al. Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia. N Engl J Med. 2015;373:1733–47.
Article CAS PubMed PubMed Central Google Scholar
• Tiacci E, De Carolis L, Simonetti E, et al. Vemurafenib plus rituximab in refractory or relapsed hairy-cell leukemia. N Engl J Med. 2021;384:1810–23. This study highlighted the value of adding rituximab to a BRAF inhibitor in achieving a higher number of CR and undetectable MRD with a chemotherapy-free combination.
Article CAS PubMed Google Scholar
Falini B, De Carolis L, Tiacci E. How I treat refractory/relapsed hairy cell leukemia with BRAF inhibitors. Blood. 2022;139:2294–305.
Article CAS PubMed Google Scholar
Caeser R, Collord G, Yao W-Q, Chen Z, Vassiliou GS, Beer PA, Du M-Q, Scott MA, Follows GA, Hodson DJ. Targeting MEK in vemurafenib-resistant hairy cell leukemia. Leukemia. 2019;33:541–5.
留言 (0)